First Patient Dosed in SOFIE Biosciences' Phase 3 Study for Pancreatic Cancer SOFIE Biosciences has commenced a pivotal Phase 3 study, dosing its first patient with [18F]FAPI-74 for pancreatic cancer, promising new diagnostic advancements.

First Patient Dosed in SOFIE Biosciences' Phase 3 Study for Pancreatic Cancer #United_States #Dulles #pancreatic_cancer #FAPI-74 #SOFIE_Biosciences

SOFIE Biosciences Marks Milestone with First Patient Dosed in Groundbreaking Phase 3 Study of [18F]FAPI-74 SOFIE Biosciences announces a significant milestone with the first patient dosed in its Phase 3 clinical trial for [18F]FAPI-74, targeting gastroesophageal cancers.

SOFIE Biosciences Marks Milestone with First Patient Dosed in Groundbreaking Phase 3 Study of [18F]FAPI-74 #USA #Dulles #oncology #FAPI-74 #SOFIE_Biosciences